Fondazione Biotecnopolo DI Siena
- UEI
- YFFWL9PP3EN5
- CAGE
- AV041
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- SAM.gov registration date
- Website
- biotecnopolo.it
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Washington University | U19AI181984 | $111,586 | |
| The Washington University | U19AI181984 | $537,083 | |
| The Washington University | U19AI181984 | $122,847 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Fundacion Instituto Leloir | CABA | — |
| Invvax, Inc. | Cypress, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Institut Pasteur De Lille | Lille, Hauts-de-France | — |
| Fondazione Per L'istituto DI Ricerca In Biomedicina (Irb) | Bellinzona, TI | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| SSI Nicaragua | Managua, MN | — |
About the company
Fondazione Biotecnopolo DI Siena is a registered non-profit organization and foundation in the United States federal procurement system, with an active SAM.gov registration that expires on May 22, 2024. While specific details about the organization's comprehensive mission are not fully disclosed in the provided documentation, the entity appears to be a research-focused foundation with significant capabilities in biotechnology and virology research. The organization is positioned to receive federal grant sub-awards, demonstrating its capacity to contribute to advanced scientific research initiatives.
The foundation has recently been involved in a complex federal grant sub-award from The Washington University focused on developing vaccines and therapeutic antibodies for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, specifically the R2P2-REVAMPP Center project. Under the leadership of Dr. Rino Rappuoli, Fondazione Biotecnopolo DI Siena is performing critical research work including identifying neutralizing antibodies from Toscana virus survivors, conducting immunogenicity studies, developing structural understanding of viral glycoproteins, and exploring vaccine development strategies. The organization's specific contributions include processing single cell sorting of virus-specific memory B cells, characterizing neutralizing antibodies, designing stabilized viral protein forms, evaluating potential vaccine platforms including mRNA and recombinant viral vector approaches, and performing comprehensive immunological assays to establish immune correlates of protection for prototype viruses.
Quick answers
Is Fondazione Biotecnopolo DI Siena registered in SAM.gov?
Fondazione Biotecnopolo DI Siena's SAM.gov registration expired on May 22, 2024.
On GovTribe
See Fondazione Biotecnopolo DI Siena's full federal record
- Similar vendors